BamSEC and AlphaSense Join Forces
Learn More

Opus Genetics Inc. – Material Contracts

NASDAQ: IRD    
Share price (5/22/26): $4.26    
Market cap (5/22/26): $347 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.6
from 10-Q 1 page Amendment No. 2 to Consulting Agreement
12/34/56
EX-10.5
from 10-Q 8 pages Waiver and Omnibus Amendment of Note Purchase Agreement and Stock Purchase and Conversion Agreement April 13, 2026
12/34/56
EX-10.2
from 8-K 22 pages Stock Purchase and Conversion Agreement
12/34/56
EX-10.1
from 8-K 114 pages Note Purchase Agreement Dated as of April 2, 2026 Among Opus Genetics, Inc. as Issuer, the Other Obligors Party Hereto, the Purchasers Party Hereto, and Opcm SA LLC as Purchaser Agent
12/34/56
EX-10.1
from 8-K 4 pages Form of Opus Genetics Inc. Change in Control Bonus Payment Agreement
12/34/56
EX-10.161
from 10-K 1 page Amendment No. 1 to Consulting Agreement
12/34/56
EX-10.2
from 8-K 20 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 39 pages Securities Purchase Agreement by and Among Opus Genetics, Inc. and the Purchasers as Set Forth Herein February 13, 2026
12/34/56
EX-10.3
from 10-Q 3 pages Side Letter to the License and Collaboration Agreement
12/34/56
EX-10.1
from 8-K 25 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 26 pages Employment Agreement
12/34/56
EX-10.2
from 10-Q 52 pages Funding and License Agreement by and Among Opus Genetics, Inc., Opustx, LLC, Eyes on the Future, and the Rdh12 Fund for Sight Dated July 22, 2025
12/34/56
EX-10.1
from 10-Q 19 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Omitted Information Has Been Replaced With Asterisks [***]
12/34/56
EX-10.33
from 10-K 26 pages Non-Exclusive License Agreement Dated as of March 2, 2023 by and Between the Trustees of the University of Pennsylvania and Opus Genetics, Inc
12/34/56
EX-10.32
from 10-K 45 pages Asset Purchase Agreement by and Between Iveric Bio Gene Therapy LLC and Opus Genetics Inc
12/34/56
EX-10.31
from 10-K 42 pages Amended and Restated License Agreement Dated as of June 15, 2022 by and Between the Trustees of the University of Pennsylvania and Opus Genetics Inc
12/34/56
EX-10.304
from 10-K 3 pages Amendment No. 4 to Exclusive License Agreement With Know-How
12/34/56
EX-10.303
from 10-K 5 pages Assignment Consent Agreement and Third Amendment to the Exclusive License Agreement With Know-How Signature Page
12/34/56
EX-10.302
from 10-K 3 pages Amendment No. 2 to Exclusive License Agreement With Know-How
12/34/56
EX-10.301
from 10-K 5 pages Amendment No. 1 to Exclusive License Agreement With Know-How
12/34/56